Antekang Cheng Received Tens of Millions of Yuan Investment from Panlin Capital in Pre-A Round, Focusing on TTF

According to VCbeat, recently, Antekang Cheng Biotechnology co., LTD. (Antekang Cheng) completed tens of millions of financing in the Pre-A round from the exclusive investor, Panlin Capital.

Antekang Cheng is a leading company of Tumor Treating Fields (TTF) technology. In recent years, it has been committed to developing personalized TTF therapy suitable for Chinese patients. Under the cooperation and strong support of the domestic professional medical association, Antekang Cheng’s clinical expert team and other multidisciplinary expert teams, the company carried out independent research and development of electric field treatment technology. At present, the product has entered the clinical trial stage.

As for the following development of Antekang Cheng, the founder Ms. Lu Jian said, "On the one hand, we will push forward the clinical trial progress in the field of glioma as soon as possible. On the other hand, we will speed up the layout of clinical trials of multiple tumor species, fully integrate clinical resources, and promote the localization of this technology as soon as possible, so as to benefit Chinese patients with cost-effective products. This round of financing will be mainly used to carry out small-sample clinical trials, large-sample clinical trials in some national multi-centers, and upgrading and upgrading of equipment to expand indications."

Shanghai Pan-Lin Asset Management co., Ltd. is a professional RMB PE fund investment management platform that is mainly engaged in assets management in equity investment and post-investment stages. Along with its managed PE funds, The company is collectively known as Panlin Capital. So far, Panlin Capital has successfully initiated and managed seven PE funds, including a healthcare industry venture capital fund and an M&A fund for the environmentally-friendly industry.